Humana (NYSE:HUM) Stock Rating Upgraded by Wall Street Zen

Humana (NYSE:HUM - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Sunday.

Other research analysts have also recently issued reports about the company. Cantor Fitzgerald reissued a "neutral" rating and set a $290.00 price objective on shares of Humana in a report on Thursday, May 1st. Wells Fargo & Company set a $348.00 price objective on Humana in a report on Friday. Mizuho raised their target price on Humana from $305.00 to $316.00 and gave the company an "outperform" rating in a research note on Wednesday, April 9th. Truist Financial lowered their target price on Humana from $280.00 to $260.00 and set a "hold" rating for the company in a research note on Wednesday. Finally, Bank of America lowered their target price on Humana from $320.00 to $260.00 and set a "neutral" rating for the company in a research note on Tuesday, June 17th. Sixteen research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $282.57.

Humana Trading Down 1.6%

Shares of HUM stock opened at $220.08 on Friday. Humana has a 12 month low of $206.87 and a 12 month high of $406.09. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.71. The business's 50 day moving average is $234.87 and its two-hundred day moving average is $257.26. The company has a market cap of $26.56 billion, a PE ratio of 15.56, a price-to-earnings-growth ratio of 1.51 and a beta of 0.44.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, beating the consensus estimate of $10.07 by $1.51. Humana had a return on equity of 14.47% and a net margin of 1.42%. The company had revenue of $32.11 billion during the quarter, compared to analysts' expectations of $32 billion. During the same period in the prior year, the business earned $7.23 earnings per share. Humana's revenue for the quarter was up 8.4% compared to the same quarter last year. Equities analysts predict that Humana will post 16.47 EPS for the current year.

Institutional Investors Weigh In On Humana

Institutional investors have recently bought and sold shares of the company. Dodge & Cox increased its position in shares of Humana by 106.7% during the 4th quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider's stock worth $2,587,345,000 after purchasing an additional 5,264,045 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Humana by 15.8% during the 4th quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider's stock worth $3,254,899,000 after purchasing an additional 1,751,857 shares during the last quarter. Norges Bank acquired a new position in shares of Humana during the 4th quarter worth approximately $416,202,000. AQR Capital Management LLC increased its position in shares of Humana by 3,257.5% during the 1st quarter. AQR Capital Management LLC now owns 1,162,600 shares of the insurance provider's stock worth $307,624,000 after purchasing an additional 1,127,973 shares during the last quarter. Finally, GAMMA Investing LLC increased its position in shares of Humana by 40,881.1% during the 1st quarter. GAMMA Investing LLC now owns 781,099 shares of the insurance provider's stock worth $2,066,790,000 after purchasing an additional 779,193 shares during the last quarter. Institutional investors own 92.38% of the company's stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.